Investigating how neutrophils contribute to lung damage in early cystic fibrosis
Official title: Neutrophil hyperexocytosis and hypochlorous acid exposure in early cystic fibrosis lung disease
Funded at Emory University · NIH-10979143 · Data updated 2026-11-12
This study is looking at how certain immune cells called neutrophils can cause lung problems in people with cystic fibrosis, especially early on, and aims to find new ways to help improve lung health by understanding how these cells interact with lung tissue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $384,601 |
| NIH project number | 5R01HL150658-03 |
| Project ID | NIH-10979143 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cystic fibrosis, particularly those in the early stages of the disease.
✕Less likely to help
Patients with cystic fibrosis who are in advanced stages of the disease or those who do not exhibit neutrophil-dominated inflammation may not benefit from this research.
What this research studies
This research focuses on understanding the role of neutrophils in causing inflammation and damage in the lungs of patients with cystic fibrosis (CF). It aims to explore how neutrophils release harmful substances that can lead to airway injury, particularly in the early stages of the disease. By studying the mechanisms behind neutrophil activity and its effects on airway epithelial cells, the research seeks to identify potential new treatments that could improve lung health in CF patients. The approach involves analyzing the interactions between neutrophils and airway cells to uncover how inflammation develops and progresses.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively reduce lung inflammation and improve the quality of life for cystic fibrosis patients.
How similar studies have gone: Previous research has indicated that targeting neutrophil activity can be beneficial in managing airway inflammation in cystic fibrosis, suggesting that this approach has potential for success.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Chandler, Joshua D — Emory University
- Study coordinator: Chandler, Joshua D
Related research
Other NIH-funded projects on the same topics.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Optimizing Treatments for People with Cystic Fibrosis on Highly Effective Modulator Therapy
A real-world study in people with cystic fibrosis on highly effective CFTR modulator therapy to understand how traditional CF treatments can be adjusted safely.
-
Elastin-like particles to deliver gene therapies for cystic fibrosis
A new nanoparticle system is being developed to deliver genetic therapies directly to the lungs of people with cystic fibrosis, including those with nonsense mutations.
-
Pharmacogenomic Predictors of Clinical Responses in Cystic Fibrosis using Targeted WGS
A study looking at how genetic information from whole-genome sequencing can predict how people with cystic fibrosis respond to medications, using a focused set of pharmacogenomic genes.
-
Ceftaroline-meropenem combo to beat MRSA in cystic fibrosis
A new combination antibiotic approach is being tested to help people with cystic fibrosis who have MRSA infections that resist standard treatments.
-
Gut microbiome in cystic fibrosis and colorectal cancer risk
Researchers are studying how the gut bacteria in adults with cystic fibrosis influence the development of colorectal cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.